Amphastar P (AMPH) revenue breakdown
By segment, Finished Pharmaceutical Products Segment is the largest at 98% of fiscal 2023 revenue, growing 15% a year over 7 years.
By product, Product is the largest at 97% of fiscal 2024 revenue, growing 20% a year over 1 years.
Revenue by segment
Fiscal years, as Amphastar P reports them in its 10-K filings; fiscal 2023 total $644M.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Finished Pharmaceutical Products Segment | $240M | $230M | $271M | $302M | $331M | $420M | $487M | $630M | 98% |
| Active Pharmaceutical Ingredient Segment | $15M | $10M | $24M | $20M | $18M | $18M | $12M | $14M | 2% |
Revenue by product
Fiscal years, as Amphastar P reports them in its 10-K filings; fiscal 2024 total $732M.
| Products | 2023 | 2024 | Share |
|---|---|---|---|
| Product | $593M | $713M | 97% |
| Other | $51M | $19M | 3% |
Revenue by region
Fiscal years, as Amphastar P reports them in its 10-K filings; fiscal 2025 total $720M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $249M | $234M | $279M | $305M | $333M | $420M | $487M | $635M | $708M | $681M | 95% |
| France | $6M | $6M | $16M | $16M | $14M | $12M | $7M | $5M | $20M | $35M | 5% |
| China | — | — | — | $1M | $3M | $6M | $5M | $5M | $4M | $3M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AMPH.
Open AMPH in InvestinglyQuestions
Where does Amphastar P make its money?
In fiscal 2023, by segment: Finished Pharmaceutical Products Segment $630M, Active Pharmaceutical Ingredient Segment $14M.
From Amphastar P's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.